HTR6
5-hydroxytryptamine receptor 6
As of the edition of 20 October 2026, HTR6 (5-hydroxytryptamine receptor 6, UniProt P50406) has 6 drugs tested at it and 6 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P50406
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Mental health; Nervous system; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 44
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 4 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Idalopirdine | Stopped | Phase 3 | none listed |
| Cerlapirdine | Stopped | Phase 2 | none listed |
| Intepirdine | Stopped | Phase 3 | none listed |
| PF-05212377 | Stopped | Phase 2 | none listed |
| Masupirdine | Active | Phase 3 | none listed |
| Landipirdine | Went quiet | Phase 2 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Engaged | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Biotie Therapies | Route A |
| GSK | Route A |
| Lundbeck | Route A |
The other 3 companies at HTR6
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at HTR6, ranked, with the facts behind eachRequest access. Nothing is shown until you do.